163 related articles for article (PubMed ID: 21858491)
1. Tafluprost: a novel prostaglandin analog for treatment of glaucoma.
Pantcheva MB; Seibold LK; Awadallah NS; Kahook MY
Adv Ther; 2011 Sep; 28(9):707-15. PubMed ID: 21858491
[TBL] [Abstract][Full Text] [Related]
2. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
3. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension.
Swymer C; Neville MW
Ann Pharmacother; 2012 Nov; 46(11):1506-10. PubMed ID: 23092867
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
Uusitalo H; Pillunat LE; Ropo A;
Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
[TBL] [Abstract][Full Text] [Related]
5. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
Erb C; Lanzl I; Seidova SF; Kimmich F
Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A
Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510
[TBL] [Abstract][Full Text] [Related]
7. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
8. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.
Traverso CE; Ropo A; Papadia M; Uusitalo H
J Ocul Pharmacol Ther; 2010 Feb; 26(1):97-104. PubMed ID: 20148656
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.
Lorenz K; Pfeiffer N
Expert Opin Pharmacother; 2014 Oct; 15(15):2255-62. PubMed ID: 25170534
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients.
Rossi GC; Pasinetti GM; Raimondi M; Ricciardelli G; Scudeller L; Blini M; Amisano A; Bianchi PE
Expert Opin Drug Saf; 2012 Jul; 11(4):519-25. PubMed ID: 22690824
[TBL] [Abstract][Full Text] [Related]
11. Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.
Hoy SM
Drugs; 2015 Oct; 75(15):1807-13. PubMed ID: 26431840
[TBL] [Abstract][Full Text] [Related]
12. Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence.
Kuwayama Y; Hashimoto M; Kakegawa R; Nomura A; Shimada F
Adv Ther; 2017 Jun; 34(6):1411-1425. PubMed ID: 28502035
[TBL] [Abstract][Full Text] [Related]
13. Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial.
Chabi A; Baranak C; Lupinacci R; Herring WJ
Int J Clin Pract; 2016 Jul; 70(7):577-86. PubMed ID: 27292765
[TBL] [Abstract][Full Text] [Related]
14. Spanish multicenter tafluprost tolerability study.
Milla E; Stirbu O; Rey A; Duch S; Buchacra O; Robles A; Navarro C; Gil R; Cordero JM
Br J Ophthalmol; 2012 Jun; 96(6):826-31. PubMed ID: 22399693
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and tolerability of preservative-free tafluprost 0.0015 % in the treatment of glaucoma and ocular hypertension].
Karhanová M; Mlčák P; Fryšák Z; Marešová K
Cesk Slov Oftalmol; 2012 Oct; 68(4):150-5. PubMed ID: 23214487
[TBL] [Abstract][Full Text] [Related]
16. Tafluprost for glaucoma.
Papadia M; Bagnis A; Scotto R; Traverso CE
Expert Opin Pharmacother; 2011 Oct; 12(15):2393-401. PubMed ID: 21916788
[TBL] [Abstract][Full Text] [Related]
17. Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: a single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group.
Rossi GC; Blini M; Scudeller L; Ricciardelli G; Depolo L; Amisano A; Bossolesi L; Pasinetti GM; Bianchi PE
J Ocul Pharmacol Ther; 2013 Nov; 29(9):821-5. PubMed ID: 23944905
[TBL] [Abstract][Full Text] [Related]
18. Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and tolerability.
Oddone F
Expert Opin Drug Saf; 2022 Oct; 21(10):1259-1268. PubMed ID: 36250245
[TBL] [Abstract][Full Text] [Related]
19. A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension.
Hommer A
Drugs Today (Barc); 2010 Jun; 46(6):409-16. PubMed ID: 20571609
[TBL] [Abstract][Full Text] [Related]
20. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
Rolle T; Spinetta R; Nuzzi R
BMC Ophthalmol; 2017 Aug; 17(1):136. PubMed ID: 28768500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
